KBC Group NV Raises Stock Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

KBC Group NV grew its position in ICU Medical, Inc. (NASDAQ:ICUI) by 2,498.0% in the 4th quarter, Holdings Channel.com reports. The fund owned 17,303 shares of the medical instruments supplier’s stock after acquiring an additional 16,637 shares during the quarter. KBC Group NV’s holdings in ICU Medical were worth $2,685,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also modified their holdings of the company. Hexagon Capital Partners LLC boosted its stake in ICU Medical by 162.7% during the 3rd quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the period. Allworth Financial LP boosted its stake in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the period. Venturi Wealth Management LLC grew its holdings in shares of ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in ICU Medical in the 2nd quarter valued at about $70,000. Finally, Point72 Hong Kong Ltd purchased a new stake in ICU Medical during the 3rd quarter valued at approximately $72,000. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

ICU Medical Trading Down 0.9 %

NASDAQ:ICUI opened at $164.36 on Friday. ICU Medical, Inc. has a 1 year low of $86.80 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The stock has a fifty day moving average price of $160.98 and a two-hundred day moving average price of $162.07. The stock has a market capitalization of $4.02 billion, a price-to-earnings ratio of -35.96 and a beta of 0.63.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. KeyCorp lifted their target price on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a research note on Wednesday, November 13th. StockNews.com upgraded shares of ICU Medical from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th. Jefferies Financial Group upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $200.00 price objective for the company in a research report on Wednesday, December 11th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, ICU Medical has an average rating of “Moderate Buy” and a consensus target price of $199.67.

Insider Activity

In related news, COO Christian B. Voigtlander sold 1,962 shares of the firm’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $169.08, for a total value of $331,734.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the business’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $162.91, for a total value of $1,954,920.00. Following the sale, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,039,245.63. The trade was a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 17,737 shares of company stock worth $2,879,752 in the last 90 days. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.